Personalized Medicine and Pharmacogenomics
This session highlights the growing role of personalized medicine and pharmacogenomics in optimizing drug therapy by tailoring treatments to an individual’s genetic and biological profile. It will explore how genetic variations influence drug metabolism, transport, target interaction, therapeutic response, and susceptibility to adverse drug reactions. The session emphasizes the integration of genomic, proteomic, and metabolomic data with clinical pharmacology to improve drug selection, dosing strategies, and treatment outcomes. Presentations will focus on clinically relevant gene–drug interactions, including polymorphisms affecting cytochrome P450 enzymes, drug transporters, and receptor targets, and how these variations can lead to treatment failure or increased toxicity if not appropriately considered. The biological basis of variability in drug response will be discussed alongside real-world examples demonstrating the benefits of pharmacogenomic-guided therapy in areas such as oncology, cardiology, psychiatry, and infectious diseases. Ethical, regulatory, and implementation challenges associated with pharmacogenomic testing in clinical practice will also be addressed, including data interpretation, accessibility, and clinical decision support. By linking biological information to clinical outcomes, this session underscores the potential of personalized medicine to reduce adverse effects, enhance therapeutic efficacy, and improve patient safety. The session aims to provide participants with a comprehensive understanding of how pharmacogenomics is transforming modern healthcare and shaping the future of precision pharmacotherapy.